| Autor: |
Maurine D. Miner, Mark Hatherill, Vidya Mave, Judith Currier, Joseph Eron, Glenda E. Gray, Sharon Nachman, Peter Kim, Sarah Read, Richard White, Anneke Hessling, Frank Cobelens, Sheral Patel, Mike Frick, Theodore Bailey, Robert Seder, Joanne Flynn, Jyothi Rengarajan, Deepak Kaushal, Willem Hanekom, Alexander Schmidt, Thomas Scriba, Elisa Nemes, Erica Andersen-Nissen, Alan Landay, Susan Dorman, Grace Aldrovandi, Lisa M. Cranmer, Cheryl Day, Lele Rangaka, Alberto Garcia-Basteiro, Andrew Fiore-Gartland, Robin Mogg, James G. Kublin, Amita Gupta, Gavin Churchyard |
| Rok vydání: |
2022 |
| DOI: |
10.21203/rs.3.rs-1605760/v1 |
| Popis: |
Many new TB vaccine candidates in the development pipeline need to be studied in people with HIV. People with HIV are at high risk of developing Mycobacterium tuberculosis (Mtb) infection and TB disease and tend to develop less robust vaccine induced immune responses. Many questions remain unanswered regarding priority vaccine indications, clinical trial design, measures of safety, immunogenicity, and efficacy considerations for people with HIV. To address these gaps, a roadmap for developing TB vaccines for people with HIV was developed through a series of symposia that posed framing questions to a panel of international experts for discussion. Framing questions specific to people with HIV included: 1) What is the use case or rationale for developing TB vaccines?; 2) What is the landscape of TB vaccines?; 3) Which vaccine candidates should be prioritized ?; 4) What are the TB vaccine trial design considerations?; 5) What is the role of immunological correlates of protection?; and 6) What are the gaps in preclinical models for studying TB vaccines? We provide a summary of our roadmap with the intention of informing TB vaccine development and the prioritization of clinical trials for inclusion of people with HIV. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
